Trial Profile
Third Phase II study of eFT508
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2018
Price :
$35
*
At a glance
- Drugs Tomivosertib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 18 Apr 2018 New trial record
- 16 Apr 2018 According to an Effector Therapeutics media release, this study is expected to be initiated by the end of 2018.